Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$17.88 USD
+0.34 (1.94%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $17.87 -0.01 (-0.06%) 6:02 PM ET
5-Strong Sell of 5 5
A Value D Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IART 17.88 +0.34(1.94%)
Will IART be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IART based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IART
Integra's (IART) Q2 Earnings and Revenues Top, Margins Down
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
IART: What are Zacks experts saying now?
Zacks Private Portfolio Services
Integra LifeSciences (IART) Q2 Earnings and Revenues Surpass Estimates
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline
Other News for IART
The Top Five short crowded stocks in each U.S. sector
Wall Street Breakfast: The Week Ahead
Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers
Integra Lifesciences Holdings Corp (IART) Trading Down 3.56% on Sep 11
Integra Lifesciences: Hold Rating Amidst Compliance Challenges and Revenue Impact with a Long-Term Recovery Outlook